[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"contact-dermatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:contact-dermatitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100652011","exploring-skin-barrier-function-recurrence-of-diabetes-device-related-contact-dermatitis-and-evaluation-of-hydrocolloid-and-silicone-based-patches-for-its-prevention-in-children-and-adolescents-with-type-1-diabetes-100652011",false,"NCT07767461","Exploring Skin Barrier Function, Recurrence of Diabetes Device-Related Contact Dermatitis and Evaluation of Hydrocolloid and Silicone-Based Patches for Its Prevention in Children and Adolescents With Type 1 Diabetes","Steno Adhesive Study 1","StenoAD1","Inclusion Criteria:\n\n* Any type of contact dermatitis due to either insulin pump or glucose sensor\n* Being between 2-18 years of age prior to inclusion\n\nExclusion Criteria:\n\n* Those who are unable to read and understand Danish and\u002For have impaired cognitive development that may interfere with the ability to answer questionnaires in Danish and\u002For be reached by phone or videocall.","ALL","2 Years","18 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to ensure that contact dermatitis is not prohibiting any person with diabetes the access to the optimal treatment.\n\nThe main questions this study aims to answer are:\n\n1. How many pediatric patients with contact dermatitis due to diabetes devices experience recurrence of contact dermatitis depending on which type of patch they use under their device.\n2. Is one type of patch (silicone-based vs. hydrocolloid patch) better than the other at preventing contact dermatitis? The group being investigated is children and adolescents aged 2-18 years with contact dermatitis caused by either an insulin pump or a continuous glucose monitor.\n\nThe participants will be asked to do different surveys on well-being and they will go to three physical visits. At the visits the the following will happen:\n\n* clinical skin examination\n* skin picture (of last used pump and sensor site as well as reportet skin reactions)\n* height and weight\n* blodsample (HbA1c and fillagrin mutations)\n* interview on skin reactions etc.\n* ultrasound of the skin\n* tape strips of the skin\n* EIS (transmit harmless electrical signal through the skin)",[28,29],"Contact Dermatitis","Type 1 Diabetes Mellitus",[31,32,33,29,34,35,36,37,38,39],"skin barrier","contact dermatitis","T1D","Hydrocolloid patch","silicone-based patch","pediatric","device-related contact dermatitis","adhesive","children and adolescents","RECRUITING","2026-08-11",{"date":43,"type":44},"2026-08-17","ACTUAL",{"date":46,"type":22},"2026-09-04",{"date":48,"type":22},"2027-05",{"name":50,"class":51},"Steno Diabetes Center Copenhagen","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":52},"100607043","novel-skin-barrier-product-versus-petrolatum-for-skin-barrier-dysfunction-100607043","NCT07183423","Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction","A Pilot Double-Blind Randomized Controlled Trial on the Efficacy and Safety of a Novel Skin Barrier Product Versus Petrolatum in Individuals With Skin Barrier Dysfunction","Inclusion Criteria:\n\n* Clinical diagnosis of mild skin barrier dysfunction, including:\n* Mild to moderate atopic dermatitis, defined as SCORAD ≤ 50, and\u002For not currently requiring topical corticosteroids or immunomodulators.\n* Mild to moderate chronic plaque psoriasis, defined as total body surface area (BSA) involved: ≤3% to 10%.\n* Contact dermatitis\n* Seasonal xerosis or clinically evident skin dryness\n* Symmetrical or bilateral test areas available (volar forearm)\n* Willing and able to provide informed consent and adhere to study procedures\n\nExclusion Criteria:\n\n* Failure to meet any of the above inclusion criteria\n* Severe atopic dermatitis or psoriasis requiring systemic or high-potency topical treatment\n* Use of corticosteroids, calcineurin inhibitors, biologics, or phototherapy within 2 weeks\n* Open wounds or evidence of secondary infection at test sites\n* Pregnant or breastfeeding women\n* Multiple nevi, tattoos, dense body hair in the test areas\n* Debilitated or immunocompromised subjects\n* Known or suspected hypersensitivity to the interventional product (or its ingredients) or petrolatum\n* Refusal or failure to comply with the schedule of visits at the test site.",{"count":61,"type":22},26,[25],"The goal of this clinical trial is to learn if a novel barrier topical product works to treat barrier dysfunction in adults. It will also learn about the safety of the novel barrier topical product. The main questions it aims to answer are:\n\nDoes the novel barrier topical product improve skin hydration, skin sebum, redness, and pigmentation? Does it improve subjective dryness and itch? Researchers will compare the novel barrier topical product to petrolatum (a gold standard occlusive barrier repair agent) to see how they are comparable in treating skin barrier dysfunction.\n\nParticipants will:\n\nApply the novel barrier topical product or petrolatum twice a day for 28 days Visit the clinic once a week for checkups and tests Keep a diary of their application of the assigned product",[65,66,67,28],"Psoriasis","Atopic Dermatitis","Xerosis",[69,70,71,72,73],"Ceramides","Emollients","Skin care","Epidermis\u002FInjuries","Coconut oil","2025-09-14",{"date":76,"type":44},"2025-09-19",{"date":78,"type":44},"2025-08-31",{"date":80,"type":22},"2025-10",{"name":82,"class":51},"Makati Medical Center"]